Harald Lanig

Prof. Dr. Harald Lanig

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2005 in Journal of Molecular Modeling
Verified
Journal Article
Closed access
PDF file
NHNadine Homeyer
Nadine Homeyer
AHAnselm Horn
Anselm Horn
HLHarald Lanig
Harald Lanig
HSHeinrich Sticht
Heinrich Sticht

7 August 2003 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
MBMartin Braun
Martin Braun
SAStefan Atalick
Stefan Atalick
DGDirk M. Guldi
Dirk M. Guldi
HLHarald Lanig
Harald Lanig
MBMichael Brettreich
Michael Brettreich
AHAndreas Hirsch
Andreas Hirsch

16 July 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KEKatharina Ehrlich
Katharina Ehrlich
AGAngela Götz
Angela Götz
SBStefan Bollinger
Stefan Bollinger
NTNuska Tschammer
Nuska Tschammer
LBLaura Bettinetti
Laura Bettinetti
PGPeter Gmeiner
Peter Gmeiner

1 July 2010 in Journal of Immunotherapy
Verified
Journal Article
Closed access
HSHeiko Singer
Heiko Singer
Christian KellnerChristian Kellner
Christian Kellner
HLHarald Lanig
Harald Lanig
MAMichael Aigner
Michael Aigner
BSBernhard Stockmeyer
Bernhard Stockmeyer
GFGeorg H. Fey
Georg H. Fey
Single-chain Fv triplebodies (sctb), consisting of a single polypeptide chain with 3 single-chain antibody variable fragments connected in tandem, were generated as antileukemic agents. A CD19-specific sctb of this format has previously been shown to be superior to a bispecific single-chain Fv antibody fragment (bsscFv) for the elimination of leukemic B-lineage cells, but corresponding targeted agents for the treatment of acute myeloid leukemia are still lacking. For this purpose, both a bsscFv and a sctb specific for CD33 and the trigger molecule CD16 (FcgammaRIII) were produced. The sctb displayed 3.5-fold greater avidity for CD33 than the bsscFv 33xds16, whereas both had close to equal affinity for CD16. In antibody-dependent cellular cytotoxicity (ADCC) reactions with human mononuclear cells as effectors, both the bsscFv 33xds16 and the sctb induced lysis of tumor cells with half maximum effective concentrations (EC50) in the low picomolar range. It is interesting to note that the sctb promoted equal lysis of human leukemia-derived cell lines at 10 to 200-fold lower concentrations than the bsscFv. Both molecules mediated ADCC of primary patient cells. In conclusion, both the bsscFv 33xds16 and the sctb 33xds16x33 eliminated acute myeloid leukemia cells in ADCC reactions, but the novel sctb format showed significantly greater specific activity.

23 March 2006 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
FBFrank R. Beierlein
Frank R. Beierlein
OOOlaf G. Othersen
Olaf G. Othersen
HLHarald Lanig
Harald Lanig
SSSiegfried Schneider
Siegfried Schneider
TCTimothy Clark
Timothy Clark

15 November 2003 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
OOOlaf G. Othersen
Olaf G. Othersen
FBFrank Beierlein
Frank Beierlein
HLHarald Lanig
Harald Lanig
TCTimothy Clark
Timothy Clark